Ads
related to: epilepsy drug market
Search results
Lexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy
Digital Journal· 7 days agoIt is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad ...
Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal
Pharmaceutical Technology via Yahoo Finance· 2 days agoThis collaboration utilises J-Brain Cargo technology to address epilepsy. JCR Pharmaceuticals...
Federal and State Approaches to Therapeutic Cannabis | JD Supra
JD Supra· 1 day agoAt the federal level, the U.S. Food and Drug Administration (FDA) has approved one drug product derived from the cannabis sativa L. plant and three synthetic ...
5 Small Drug Stocks to Buy From a Recovering Industry
Zacks via Yahoo Finance· 6 days agoInnovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX,...
CCMB, Aganitha to apply Generative AI for therapeutic design, research
Investing.com· 1 day agoCCMB, a part of the Council of Scientific & Industrial Research (CSIR), and Aganitha, which combines...
Fit for a dog? The latest science on CBD for pets
Popular Science via Yahoo News· 6 days agoThis article was originally featured on Knowable Magazine. 13-year-old Norwich terrier, previously limping and stiff, able to enjoy walks again. A toy...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoThe study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant ...
Supernus Pharmaceuticals stock maintains Buy rating on SPN-817 phase II trial By Investing.com
Investing.com· 6 days agoOn Friday, Supernus Pharmaceuticals (NASDAQ:SUPN) sustained its Buy rating alongside a steady stock...
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer - Jazz...
Benzinga· 20 hours agoTarget Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract